Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

Vince B. C. Biemans; C. Janneke van der Woude; Gerard Dijkstra; Andrea E. van der Meulen-de Jong; Bas Oldenburg; Nanne K. de Boer; Mark Loewenberg; Nidhi Srivastava; Alexander G. L. Bodelier; Rachel L. West; Jeroen M. Jansen; Annemarie C. de Vries; Jeoffrey J. L. Haans; Dirk J. de Jong; Marie J. Pierik; Frank Hoentjen; Dutch Initiative Crohn and Colitis

doi:10.1002/cpt.1712

Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

Vince B. C. Biemans
, C. Janneke van der Woude
, Gerard Dijkstra
, Andrea E. van der Meulen-de Jong
, Bas Oldenburg
, Nanne K. de Boer
, Mark Loewenberg
, Nidhi Srivastava
, Alexander G. L. Bodelier
, Rachel L. West
, Jeroen M. Jansen
, Annemarie C. de Vries
, Jeoffrey J. L. Haans
, Dirk J. de Jong
, Marie J. Pierik
, Frank Hoentjen^*
, Dutch Initiative Crohn and Colitis

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index

Original language	English
Pages (from-to)	1189-1199
Number of pages	11
Journal	Clinical Pharmacology & Therapeutics
Volume	107
Issue number	5
Early online date	11 Dec 2019
DOIs	https://doi.org/10.1002/cpt.1712
Publication status	Published - May 2020

Keywords

LONG-TERM EFFECTIVENESS
MAINTENANCE THERAPY
MULTICENTER COHORT
INDUCTION
SAFETY
IMPACT

Access to Document

10.1002/cpt.1712Licence: CC BY-NC

Cite this

Biemans, V. B. C., van der Woude, C. J., Dijkstra, G., van der Meulen-de Jong, A. E., Oldenburg, B., de Boer, N. K., Loewenberg, M., Srivastava, N., Bodelier, A. G. L., West, R. L., Jansen, J. M., de Vries, A. C., Haans, J. J. L., de Jong, D. J., Pierik, M. J., Hoentjen, F., & Dutch Initiative Crohn and Colitis (2020). Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab. Clinical Pharmacology & Therapeutics, 107(5), 1189-1199. https://doi.org/10.1002/cpt.1712

@article{1fbe1c747c3a4e0eb5acfbd9b215795a,

title = "Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab",

abstract = "Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index",

keywords = "LONG-TERM EFFECTIVENESS, MAINTENANCE THERAPY, MULTICENTER COHORT, INDUCTION, SAFETY, IMPACT",

author = "Biemans, \{Vince B. C.\} and \{van der Woude\}, \{C. Janneke\} and Gerard Dijkstra and \{van der Meulen-de Jong\}, \{Andrea E.\} and Bas Oldenburg and \{de Boer\}, \{Nanne K.\} and Mark Loewenberg and Nidhi Srivastava and Bodelier, \{Alexander G. L.\} and West, \{Rachel L.\} and Jansen, \{Jeroen M.\} and \{de Vries\}, \{Annemarie C.\} and Haans, \{Jeoffrey J. L.\} and \{de Jong\}, \{Dirk J.\} and Pierik, \{Marie J.\} and Frank Hoentjen and \{Dutch Initiative Crohn and Colitis\}",

note = "Publisher Copyright: {\textcopyright} 2019 The Authors. Clinical Pharmacology \& Therapeutics published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics.",

year = "2020",

month = may,

doi = "10.1002/cpt.1712",

language = "English",

volume = "107",

pages = "1189--1199",

journal = "Clinical Pharmacology \& Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "5",

}

Biemans, VBC, van der Woude, CJ, Dijkstra, G, van der Meulen-de Jong, AE, Oldenburg, B, de Boer, NK, Loewenberg, M, Srivastava, N, Bodelier, AGL, West, RL, Jansen, JM, de Vries, AC, Haans, JJL, de Jong, DJ, Pierik, MJ, Hoentjen, F & Dutch Initiative Crohn and Colitis 2020, 'Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab', Clinical Pharmacology & Therapeutics, vol. 107, no. 5, pp. 1189-1199. https://doi.org/10.1002/cpt.1712

Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab. / Biemans, Vince B. C.; van der Woude, C. Janneke; Dijkstra, Gerard et al.
In: Clinical Pharmacology & Therapeutics, Vol. 107, No. 5, 05.2020, p. 1189-1199.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Vedolizumab for Inflammatory Bowel Disease

T2 - Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

AU - Biemans, Vince B. C.

AU - van der Woude, C. Janneke

AU - Dijkstra, Gerard

AU - van der Meulen-de Jong, Andrea E.

AU - Oldenburg, Bas

AU - de Boer, Nanne K.

AU - Loewenberg, Mark

AU - Srivastava, Nidhi

AU - Bodelier, Alexander G. L.

AU - West, Rachel L.

AU - Jansen, Jeroen M.

AU - de Vries, Annemarie C.

AU - Haans, Jeoffrey J. L.

AU - de Jong, Dirk J.

AU - Pierik, Marie J.

AU - Hoentjen, Frank

AU - Dutch Initiative Crohn and Colitis

PY - 2020/5

Y1 - 2020/5

N2 - Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index

AB - Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index

KW - LONG-TERM EFFECTIVENESS

KW - MAINTENANCE THERAPY

KW - MULTICENTER COHORT

KW - INDUCTION

KW - SAFETY

KW - IMPACT

U2 - 10.1002/cpt.1712

DO - 10.1002/cpt.1712

M3 - Article

C2 - 31677154

SN - 0009-9236

VL - 107

SP - 1189

EP - 1199

JO - Clinical Pharmacology & Therapeutics

JF - Clinical Pharmacology & Therapeutics

IS - 5

ER -

Biemans VBC, van der Woude CJ, Dijkstra G, van der Meulen-de Jong AE, Oldenburg B, de Boer NK et al. Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab. Clinical Pharmacology & Therapeutics. 2020 May;107(5):1189-1199. Epub 2019 Dec 11. doi: 10.1002/cpt.1712

Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study ICC Registry - Vedolizumab

Abstract

Keywords

Access to Document

Fingerprint

Cite this